Novo Nordisk’s Semaglutide Achieves ‘Cardiodiabesity’ Label

With Wegovy’s new indication for cardiovascular risk reduction in patients with overweight and obesity, the migration of diabetes drugs from a single disease state to address a host of interrelated conditions reaches a new milestone.